Clinical Trials Browser

Phase 2 × INDUSTRY × quisinostat × Clear all

NCT02948075 2018-06-27

Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Phase 2 Completed

Ovarian Neoplasms

NCT01486277 2016-11-03

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Phase 2 Completed

DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous